Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Werner Kalow

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Human Genomics|December 14, 2004
Human pharmacogenomics: the development of a scienceWerner Kalow
Expert Opinion on Pharmacotherapy|July 15, 2005
A pharmacogeneticist's look at drug effects and the drug development process: an overviewWerner Kalow
Methods in Molecular Biology (Clifton, N.J.)|August 16, 2005
Pharmacogenomics: historical perspective and current statusWerner Kalow
Fundamental & Clinical Pharmacology|February 27, 2003
Pharmacogenetics and personalised medicineWerner Kalow
Clinical Pharmacology and Therapeutics|January 25, 2003
Medical practice, race, and drug useWerner Kalow
Mcgill Journal of Medicine : MJM : an International Forum for the Advancement of Medical Sciences by Students|June 5, 2008
Personalized medicine: some thoughtsWerner Kalow
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|March 11, 2004
Atypical plasma cholinesterase. A personal discovery story: a tale of three citiesWerner Kalow
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|December 4, 2008
The relation of plasma cholinesterases to response to clinical doses of succinylcholineWerner Kalow
Pharmacogenetics and Genomics|December 14, 2007
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazineEleni Aklillu, Werner Kalow, Laszlo Endrenyi, et al.
European Journal of Clinical Pharmacology|August 20, 2002
Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expressionSherwin K B Sy, Antonio Ciaccia, Wei Li, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Human Genomics|December 14, 2004
Human pharmacogenomics: the development of a scienceWerner Kalow
Expert Opinion on Pharmacotherapy|July 15, 2005
A pharmacogeneticist's look at drug effects and the drug development process: an overviewWerner Kalow
Methods in Molecular Biology (Clifton, N.J.)|August 16, 2005
Pharmacogenomics: historical perspective and current statusWerner Kalow
Fundamental & Clinical Pharmacology|February 27, 2003
Pharmacogenetics and personalised medicineWerner Kalow
Clinical Pharmacology and Therapeutics|January 25, 2003
Medical practice, race, and drug useWerner Kalow
Mcgill Journal of Medicine : MJM : an International Forum for the Advancement of Medical Sciences by Students|June 5, 2008
Personalized medicine: some thoughtsWerner Kalow
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|March 11, 2004
Atypical plasma cholinesterase. A personal discovery story: a tale of three citiesWerner Kalow
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|December 4, 2008
The relation of plasma cholinesterases to response to clinical doses of succinylcholineWerner Kalow
Pharmacogenetics and Genomics|December 14, 2007
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazineEleni Aklillu, Werner Kalow, Laszlo Endrenyi, et al.
European Journal of Clinical Pharmacology|August 20, 2002
Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expressionSherwin K B Sy, Antonio Ciaccia, Wei Li, et al.
Pageof 2